Breakthrough Pill Extends Pancreatic Cancer Survival | Chattanooga News

FDA just approved a groundbreaking new pill for pancreatic cancer — the most common and deadliest form — marking a major leap forward in treatment. Called daraxonrasib (sold as Rasonque), it’s the first drug to target a long-elusive protein that fuels tumor growth, offering patients nearly double the survival time compared to standard chemo — from 6.7 to 13.2 months — with fewer side effects. The approval came six months early, fueled by public attention after a former senator credited it for pain relief, and an expanded access program let more patients try it sooner. Targeting KRAS mutations — once considered “undruggable” — this breakthrough could revolutionize not just pancreatic cancer but other cancers too, with drugmakers already exploring its potential for lung cancer and beyond. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ea42f6304280f272